2. Search Result
Search Result
Results for "

ML 2-14

" in MedChemExpress (MCE) Product Catalog:

91

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

2

Biochemical Assay Reagents

3

Peptides

2

Inhibitory Antibodies

3

Natural
Products

2

Isotope-Labeled Compounds

19

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-132991
    ML 2-14
    1 Publications Verification

    		 PROTACs Epigenetic Reader Domain Cancer
    ML 2-14 is a PROTAC targeting BRD4 with a C4 alkyl linker. ML 2-14 consists of the E3 ligase ligand EN219 (HY-115715) (bule part), the target protein ligand JQ-1 (HY-13030) (red part), and the PROTAC linker (balck part). ML 2-14 can effectively degrade BRD4 in 231MFP breast cancer cells, and this effect can be reversed by the proteasome inhibitor Bortezomib (HY-10227) and the E1 activase inhibitor TAK-243 (HY-100487) .
    ML 2-14
  • HY-168708
    AH2-14c

    		Histone Demethylase Apoptosis Cancer
    AH2-14c is an inhibitor for DNA demethylase ALKBH2. AH2-14c inhibits the cell viability (IC50 is 4.56 µM) and migration of GBM U87. AH2-14c regulates the expression of apoptosis-related genes, and induces apoptosis in GBM U87 cell .
    AH2-14c
  • HY-158116
    VVD-214

    RO7589831; VVD-133214

    		 DNA/RNA Synthesis Cancer
    VVD-214 is a synthetic lethal allosteric inhibitor of WRN helicase with an IC50 of 0.1316 µM. VVD-214 covalently binds to cysteine 727 of WRN and inhibits ATP hydrolysis and helicase activity. VVD-214 is potent in causing double-stranded DNA breaks, nuclear swelling, and cell death in high microsatellite instability (MSI) cancers .
    VVD-214
  • HY-12501A
    ITI-214
    3 Publications Verification

    		 Phosphodiesterase (PDE) Neurological Disease
    ITI-214 is a potent, CNS-active, orally bioavailable PDE1 inhibitor (Ki of 58 pM) with excellent selectivity against other PDE family members and against a panel of enzymes, receptors, transporters and ion channels. ITI-214 inhibits recombinant full-length human PDE1A, PDE1B and PDE1C with Kis of 33 pM, 380 pM and 35 pM, respectively. ITI-214 shows efficacy in various animal models of motor and cognitive functions .
    ITI-214
  • HY-P5489
    IGRP(206-214)

    		IFNAR Metabolic Disease Inflammation/Immunology
    IGRP(206-214) is a biological active peptide. IGRP(206-214) corresponds to residues 206-214 of murine islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP). IGRP(206-214) is T cells specific for proinsulin and IGRP induces diabetes in non-obese diabetic (NOD) mice .
    IGRP(206-214)
  • HY-12045
    HMN-214
    4 Publications Verification

    IVX-214

    		 Polo-like Kinase (PLK) Cancer
    HMN-214, an orally bioavailable proagent of HMN-176, is an inhibitor of polo-like kinase-1 (plk1), with antitumor activity.
    HMN-214
  • HY-172537
    Indolimine-214

    		DNA/RNA Synthesis Inflammation/Immunology Cancer
    Indolimine-214 is a metabolite of M. morganii Indolimine-214 increases the level of γH2AX in HeLa cells. Indolimine-214 can be used in the study of inflammatory bowel disease (IBD) and colorectal cancer (CRC) .
    Indolimine-214
  • HY-150553
    COX-2-IN-28

    		COX Inflammation/Immunology
    COX-2-IN-28 is a potent and selective COX-2 inhibitor with IC50 values of 0.054, 2.14, 13.21 µM for COX-2, 15-LOX, COX-1,respectively .
    COX-2-IN-28
  • HY-164455
    AJI-214

    		STAT JAK Aurora Kinase Mitosis Inflammation/Immunology
    AJI-214 is a dual-target inhibitor of Aurora kinase A and JAK2. AJI-214 directly blocks Aurora kinase A to inhibit T cell mitotic progression and cell polarity, and inhibits JAK2 activation to inhibit STAT3 phosphorylation, thereby reducing the differentiation of TH1 and TH17 cells. AJI-214 can be used in studies on regulating immune responses and preventing graft-versus-host disease (GVHD) .
    AJI-214
  • HY-12501
    ITI-214 free base

    		Phosphodiesterase (PDE) Neurological Disease
    ITI-214 free base is a potent, CNS-active, orally bioavailable PDE1 inhibitor (Ki of 58 pM) with excellent selectivity against other PDE family members and against a panel of enzymes, receptors, transporters and ion channels. ITI-214 free base inhibits recombinant full-length human PDE1A, PDE1B and PDE1C with Kis of 33 pM, 380 pM and 35 pM, respectively. ITI-214 free base shows efficacy in various animal models of motor and cognitive functions .
    ITI-214 free base
  • HY-100753
    STAT3-IN-1
    Maximum Cited Publications
    10 Publications Verification

    		 STAT Apoptosis Cancer
    STAT3-IN-1 (compound 7d) is an excellent, selective and orally active STAT3 inhibitor, with IC50 values of 1.82 μM and 2.14 μM in HT29 and MDA-MB 231 cells, respectively. STAT3-IN-1 (compound 7d) induces tumor cells apoptosis .
    STAT3-IN-1
  • HY-145931
    CC214-2

    		mTOR Autophagy Cancer
    CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo .
    CC214-2
  • HY-154910
    CC214-1

    		mTOR Cancer
    CC214-1 is a potentially efficacious mTOR inhibitor that induces autophagy ,with an IC50 is 0.002 μM. CC214-1 proved to be useful as an in vitro tool compound for the exploration of mTOR kinase biology. CC214-1 can be used for Glioblastoma study .
    CC214-1
  • HY-159158
    COX-1/2-IN-8

    		COX Inflammation/Immunology
    COX-1/2-IN-8 (compound 11f) is an orally active and potent inhibitor of COX-1 and COX-2, with IC50 values of 2.14 and 0.58 µM, respectively. COX-1/2-IN-8 displays a higher significant anti-inflammatory activity than Celecoxib (HY-14398) .
    COX-1/2-IN-8
  • HY-RS14698
    TMEM214 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    TMEM214 Human Pre-designed siRNA Set A contains three designed siRNAs for TMEM214 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TMEM214 Human Pre-designed siRNA Set A
    TMEM214 Human Pre-designed siRNA Set A
  • HY-RS09692
    NUP214 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    NUP214 Human Pre-designed siRNA Set A contains three designed siRNAs for NUP214 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    NUP214 Human Pre-designed siRNA Set A
    NUP214 Human Pre-designed siRNA Set A
  • HY-RS12079
    RNF214 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    RNF214 Human Pre-designed siRNA Set A contains three designed siRNAs for RNF214 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    RNF214 Human Pre-designed siRNA Set A
    RNF214 Human Pre-designed siRNA Set A
  • HY-124083
    MPT0B214

    		Microtubule/Tubulin Apoptosis Caspase Mitochondrial Metabolism Cancer
    MPT0B214 is a microtubule inhibitor that strongly binds to the colchicine binding site of tubulin, preventing tubulin polymerization. MPT0B214 induces apoptosis through a mitochondrial/caspase 9 dependent pathway and shows cytotoxicity across various human tumor cell lines. MPT0B214 can be used for cancer research .
    MPT0B214
  • HY-P3813
    Tyrosinase (206-214), human

    		Tyrosinase Inflammation/Immunology Cancer
    Tyrosinase (206-214), human (AFLPWHRLF), a 9-amino acid peptide, is a tyrosinase epitope. Tyrosinase (206-214), human can be recognized by HLA-A24 restricted, tumor-infiltrating lymphocytes (TIL) .
    Tyrosinase (206-214), human
  • HY-P4149
    Imsamotide

    IDO194-214

    		 Indoleamine 2,3-Dioxygenase (IDO) Inflammation/Immunology Cancer
    Imsamotide (IDO194-214) is a Indoleamine 2,3-Dioxygenase (IDO) peptide with sequences of DTLLKALLEIASCLEKALQVF, the IDO194-214. Imsamotide is also an immunological agent for active immunization, as well as an antineoplastic agent .
    Imsamotide
  • HY-W250971
    16-Doxylstearic acid (Free radical)

    16-DSA (Free radical)

    		 Endogenous Metabolite Metabolic Disease
    16-DOXYL-stearic Acid Free Radical (2-(14-Carboxytetradecyl)-2-ethyl-4,4-dimethyl-3-oxazolidinyloxy Free Radical; 16-DSA) is a form of stearic acid containing a 4,4-dimethyl-3-oxazolidinyloxy (DOXYL) group that forms a hydrophobic spin label. It is often used to study molecular aspects of membranes and hydrophobic proteins.
    16-Doxylstearic acid (Free radical)
  • HY-14945
    Remogliflozin etabonate

    GSK189075

    		 SGLT Metabolic Disease
    Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models .
    Remogliflozin etabonate
  • HY-175003
    HV1-IN-2

    		Others Cancer
    HV1-IN-2 (Compound 14c) is a human voltage-gated proton channel (HV1) inhibitor with an IC50 of 2.14 μM. HV1-IN-2 has a potent anticancer activity with significant antiproliferative effects against THP-1 and MCF-7 cells. HV1-IN-2 can be used for cancers research, such as colorectal tumours, leukaemia, and breast cancer .
    HV1-IN-2
  • HY-144761
    TOPK-p38/JNK-IN-1

    		JNK Cancer
    TOPK-p38/JNK-IN-1 (Compound B12) is an orally active TOPK-p38/JNK signaling pathway inhibitor with the IC50 value of 2.14 µM for NO production. TOPK-p38/JNK-IN-1 shows anti-inflammatory activities. TOPK-p38/JNK-IN-1 also inhibits phosphorylate downstream related proteins and avoids degradation of TOPK .
    TOPK-p38/JNK-IN-1
  • HY-124582
    NEO214
    1 Publications Verification

    		 Autophagy mTOR Cancer
    NEO214 is an autophagy inhibitor and a covalent conjugate of the PDE4 inhibitor Rolipram (HY-16900) and perillyl alcohol (HY-N7000). It has anti-cancer activity and blood-brain barrier (BBB) permeability. Over sex. NEO214 prevents autophagy-lysosome fusion, thereby blocking autophagic flux and triggering glioma cell death. The process involves mTOR activation, andTFEB(Transcription Factor EB) aggregation. NEO214 inhibitionMacroautophagy/autophagy in glioblastoma cells has the potential to overcome chemotherapy resistance in glioblastoma .
    NEO214
  • HY-147860
    EGFR-IN-61

    		EGFR Cancer
    EGFR-IN-61 (compound 22a) is a potent EGFR kinase inhibitor, with IC50 values of 42 nM (L858R/T790 M), 137 nM (L858R/T790 M/C797S), and 743 nM (WT), respectively. EGFR-IN-61 shows antiproliferative activity against A549 and H1975 cell lines, with IC50 values of 2.14 and 1.82 μM, respectively .
    EGFR-IN-61
  • HY-W010668
    Quinine sulfate hydrate
    5 Publications Verification

    		 Flavivirus Dengue Virus Parasite Potassium Channel Others
    Quinine sulfate hydrate (2:1:4) is an orally active alkaloid extracted from cinchona bark and can be used in anti-malarial studies. Quinine sulfate hydrate (2:1:4) is a potassium channel inhibitor that inhibits WT mouse Slo3 (KCa5.1) channel currents evoked by voltage pulses to +100 mV with an IC50 of 169 μM .
    Quinine sulfate hydrate
  • HY-75270
    tert-Butyl 2-(1-(4-(ethoxycarbonyl)phenyl)ethylidene)hydrazinecarboxylate

    		Drug Intermediate Others
    tert-Butyl 2-(1-(4-(ethoxycarbonyl)phenyl)ethylidene)hydrazinecarboxylate is a drug intermediate for synthesis of various active compounds.
    tert-Butyl 2-(1-(4-(ethoxycarbonyl)phenyl)ethylidene)hydrazinecarboxylate
  • HY-W049455
    (S)-2-(1,4-Dibenzylpiperazin-2-yl)acetonitrile

    		Drug Intermediate Others
    (S)-2-(1,4-Dibenzylpiperazin-2-yl)acetonitrile is a drug intermediate for synthesis of various active compounds.
    (S)-2-(1,4-Dibenzylpiperazin-2-yl)acetonitrile
  • HY-W030120
    2-(1-(4-Fluorobenzyl)-1H-indol-3-yl)acetic acid

    		Cannabinoid Receptor Neurological Disease
    2-(1-(4-Fluorobenzyl)-1H-indol-3-yl)acetic acid is structurally similar to cannabinoid.
    2-(1-(4-Fluorobenzyl)-1H-indol-3-yl)acetic acid
  • HY-101442
    SR9238
    1 Publications Verification

    		 LXR Metabolic Disease
    SR9238 is a synthetic liver X receptor (LXR) inverse agonist with IC50s of 214 nM and 43 nM for LXRα and LXRβ, respectively.
    SR9238
  • HY-W010668R
    Quinine sulfate hydrate (Standard)

    		Flavivirus Dengue Virus Reference Standards Parasite Potassium Channel Others
    Quinine (sulfate hydrate) (Standard) is the analytical standard of Quinine (sulfate hydrate). This product is intended for research and analytical applications. Quinine sulfate hydrate (2:1:4) is an orally active alkaloid extracted from cinchona bark and can be used in anti-malarial studies. Quinine sulfate hydrate (2:1:4) is a potassium channel inhibitor that inhibits WT mouse Slo3 (KCa5.1) channel currents evoked by voltage pulses to +100?mV with an IC50 of 169 μM .
    Quinine sulfate hydrate (Standard)
  • HY-117651R
    2-Fluoropalmitic acid (Standard)

    		Reference Standards Acyltransferase Cancer
    Quinine (sulfate hydrate) (Standard) is the analytical standard of Quinine (sulfate hydrate). This product is intended for research and analytical applications. Quinine sulfate hydrate (2:1:4) is an orally active alkaloid extracted from cinchona bark and can be used in anti-malarial studies. Quinine sulfate hydrate (2:1:4) is a potassium channel inhibitor that inhibits WT mouse Slo3 (KCa5.1) channel currents evoked by voltage pulses to +100?mV with an IC50 of 169 μM .
    2-Fluoropalmitic acid (Standard)
  • HY-108597
    TC-S 7005
    4 Publications Verification

    		 Polo-like Kinase (PLK) Cardiovascular Disease Inflammation/Immunology
    TC-S 7005 is a Polo-like kinases (Plks) inhibitor with IC50s of 4 nM, 24 nM and 214 nM for Plk2, Plk3, and Plk1, respectively .
    TC-S 7005
  • HY-158387
    Anticancer agent 214

    		Topoisomerase Cancer
    Anticancer agent 214 (2) is a Camptothecin compound, with IC50 values of 2.6 nM and 15.7 nM in MCF-7 cells and MDA-MB-231 cells, respectively .
    Anticancer agent 214
  • HY-R00445
    hsa-miR-214-3p mimic

    		MicroRNA Cancer
    hsa-miR-214-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
    hsa-miR-214-3p mimic
    hsa-miR-214-3p mimic
  • HY-R00446
    hsa-miR-214-5p mimic

    		MicroRNA Cancer
    hsa-miR-214-5p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
    hsa-miR-214-5p mimic
    hsa-miR-214-5p mimic
  • HY-R04303
    rno-miR-214-3p mimic

    		MicroRNA Cancer
    rno-miR-214-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
    rno-miR-214-3p mimic
    rno-miR-214-3p mimic
  • HY-R04304
    rno-miR-214-5p mimic

    		MicroRNA Cancer
    rno-miR-214-5p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
    rno-miR-214-5p mimic
    rno-miR-214-5p mimic
  • HY-W182770
    GPR84 agonist-1

    		GPR84 Inflammation/Immunology
    GPR84 agonist-1 (Compound LY214-5) is a GPR84 agonist, with an EC50 of 2.479 μM. GPR84 agonist-1 can be used for the research of septicemia .
    GPR84 agonist-1
  • HY-167711
    Sirtuin modulator 9

    		Mitochondrial Metabolism Metabolic Disease Inflammation/Immunology Cancer
    Sirtuin modulator 9 (Compound 214) is a sirtuin-modulating compound that may be used to increase lifespan of cells and in diseases related to aging, inflammation and cancer as well as diseases that would benefit from increased mitochondrial activity .
    Sirtuin modulator 9
  • HY-145408
    CDK7/9-IN-1

    		CDK Cancer
    CDK7/9-IN-1 is a cyclin-dependent kinases 7/9 (CDK7/9) inhibitor. CDK7/9-IN-1 selectively inhibits CDK7 over CDK9. CDK7/9-IN-1 inhibits CDK7 with IC50s of 0.0656 μM and 0.00574 μM without pre-incubation and after 3 hours pre-incubation, respectively. CDK7/9-IN-1 inhibits CDK9 with an IC50 of 2.14 μM after 3 hours pre-incubation. CDK7/9-IN-1 can be used for the research of cancer .
    CDK7/9-IN-1
  • HY-101442R
    SR9238 (Standard)

    		Reference Standards LXR Metabolic Disease
    SR9238 (Standard) is the analytical standard of SR9238. This product is intended for research and analytical applications. SR9238 is a synthetic liver X receptor (LXR) inverse agonist with IC50s of 214 nM and 43 nM for LXRα and LXRβ, respectively.
    SR9238 (Standard)
  • HY-175302
    TRK-IN-32

    		Trk Receptor Apoptosis Cancer
    TRK-IN-32 is a potent TRK inhibitor. TRK-IN-32 potently inhibits TRK WT, TRK G595R and TRK G667C with IC50 values of 0.08 nM, 2.14 nM and 0.68 nM, respectively. TRK-IN-32 also demonstrates antiproliferative activity against a panel of Ba/F3 cell lines transformed with wild type, xDFG, solvent-front as well as gatekeeper mutant TRK fusion proteins. TRK-IN-32 induces apoptosis of Ba/F3-TRKA WT and Ba/F3-TRKA G667C cells.TRK-IN-32 can be used for the study of various cancers (such as thyroid cancer, secretory breast carcinoma) .
    TRK-IN-32
  • HY-164049
    TG8-260

    		Prostaglandin Receptor Inflammation/Immunology
    TG8-260 is a second-generation EP2 antagonist developed to alleviate the pathology of central nervous system and peripheral diseases driven by inflammation. TG8-260 can reduce neuroinflammation and gliosis in the hippocampus of rats after pilocarpine-induced persistent epileptic status. Pharmacokinetic data of TG8-260 showed that its plasma half-life was 2.14 hours and its oral bioavailability was 77.3%. TG8-260 is also a potent inhibitor of CYP450 and shows antagonistic activity in inhibiting EP2 receptor-mediated inflammatory gene expression in BV2-hEP2 microglia, which is suitable for studying anti-inflammatory pathways in animal models of peripheral inflammatory diseases .
    TG8-260
  • HY-163159
    NP3-562

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NP3-562 is a potent, orally active, tricyclic NLRP3 Inhibitor, with an IC50 of 214 nM. NP3-562 (30 mg/kg, p.o.) inhibits IL-1β release in a mouse acute peritonitis model .
    NP3-562
  • HY-150053
    JNK-IN-11

    		JNK Neurological Disease
    JNK-IN-11 (compound 1) is a potent JNK inhibitor with an IC50 value of 2.2, 21.4, 1.8 µM for JNK1, JNK2, JNK3, respectively. JNK-IN-11 has the potential for the research of alzheimer and parkinson disease .
    JNK-IN-11
  • HY-B1402B
    Hydrocortisone hemisuccinate sodium
    1 Publications Verification

    Hydrocortisone 21-hemisuccinate sodium

    		 Glucocorticoid Receptor Cardiovascular Disease Metabolic Disease
    Hydrocortisone hemisuccinate sodium is an orally active physiological glucocorticoid. Hydrocortisone hemisuccinate sodium inhibits proinflammatory cytokine activity, with IC50s of 6.7 and 21.4 μM for IL-6 and IL-3, respectively. Hydrocortisone hemisuccinate sodium can be used for the research of ulcerative colitis (UC) .
    Hydrocortisone hemisuccinate sodium
  • HY-168240
    NMDAR antagonist 2

    		iGluR Neurological Disease
    NMDAR antagonist 2 (compound 3I) is a CNS penetrant NMDAR antagonist with the IC50 of 4.42 μM and 214.75 μM for hGluN1/hGluN2A at −60 mV or 40 mV membrane potentials, respectively. NMDAR antagonist 2 can reduce hippocampal damage .
    NMDAR antagonist 2
  • HY-RI04303
    rno-miR-214-3p inhibitor

    		MicroRNA Cancer
    rno-miR-214-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    rno-miR-214-3p inhibitor
    rno-miR-214-3p inhibitor

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: